News | November 02, 2008

ACIST, Nova to Co-Distribute Creatinine Meter

November 3, 2008 - ACIST Medical Systems Inc. (a Bracco Group company), signed a distribution agreement for the StatSensor Creatinine Meter with Nova Biomedical, in which the ACIST and Nova teams will co-exclusively market and distribute the StatSensor Creatinine Meter into the medical fields of radiology and cardiology within North America.

Within this new distribution structure, both ACIST and Nova will focus on providing its customers with continuity for the StatSensor solution from point of care deployment in imaging modalities where iodine- and gadolinium-derived intravenous contrast agents are administered, to platform management and its connectivity into the clinical laboratory.

ACIST will continue to support customers who have previously purchased the StatSensor Creatinine Meter under the E-Z-Chem brand name from E-Z-EM Inc. prior to the acquisition of certain assets by ACIST Medical Systems.

The StatSensor Creatinine device measures a patient's blood creatinine level and calculates their eGFR (estimated glomerular filtration rate) prior to contrast agent administration via a finger prick. Blood creatinine levels and eGFR are key clinical factors, allowing the clinician to assess patient renal function and eligibility for IV contrast administration. The test is designed to minimize the potential for CIN (Contrast Induced Nephropathy), which can include such serious conditions as renal impairment from iodine based contrast to NSF (Nephrogenic Systemic Fibrosis) from gadolinium based contrast.

For more information: www.acistmedical.com

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...